Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed FCF Margin for 4 consecutive years, with 6.41% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 538647.0% to 6.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 146.74% through Dec 2025, up 178074.0% year-over-year, with the annual reading at 146.74% for FY2025, 178074.0% up from the prior year.
  • FCF Margin for Q4 2025 was 6.41% at Orchestra BioMed Holdings, up from 1725.9% in the prior quarter.
  • The five-year high for FCF Margin was 6.41% in Q4 2025, with the low at 5392.89% in Q4 2024.
  • Average FCF Margin over 4 years is 1806.13%, with a median of 1560.42% recorded in 2024.
  • The sharpest move saw FCF Margin tumbled -338976bps in 2023, then skyrocketed 538647bps in 2025.
  • Over 4 years, FCF Margin stood at 797.64% in 2022, then crashed by -425bps to 4187.4% in 2023, then decreased by -29bps to 5392.89% in 2024, then surged by 100bps to 6.41% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 6.41%, 1725.9%, and 1861.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.